Business
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates" NEWTON, Mass., April 24, 2024
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"Invited to Present Updated Endometrial Cancer Data During Special Session \"ASCO Plenary Series: Rapid Abstract Updates\"\nNEWTON, Mass., April 24, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO Annual Meeting) being held May 31 - June 4 in Chicago, IL. The Company is pleased to have received an invitation to present updated Endometrial Cancer data during a special session called \"ASCO Plenary Series: Rapid Abstract Updates.\"\n\n \n \n \n \n \n \n\n \nA highlight at the 2024 ASCO Annual Meeting includes a rapid oral abstract update of long-term follow-up of selinexor maintenance in patients with TP53wt advanced or recurrent endometrial cancer – a pre-specified subgroup analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study.\n\"As we follow the endometrial cancer patients whose tumors are TP53wt and evaluate the long-term benefit, our confidence for selinexor to provide meaningful benefit for patients continues to grow,\" said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. \"We are excited about the advancement of our three, phase three programs in areas of high unmet need in endometrial cancer, myelofibrosis, and multiple myeloma.\"\nDetails for the 2024 ASCO Annual Meeting abstracts are as follows:\nAbstract Title\nPresentation Type\nAbstract #\nSession Date/Time\nEndometrial Cancer\nUpdates on Abstract 427956: Long-Term Follow up of Selinexor Maintenance in Patients with TP53wt Advanced or Recurrent Endometrial Cancer—A Pre-Specified Subgroup Analysis from the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study(Rapid abstract update presentation following July 25, 2023 Plenary Series)\nRapid Oral\n427956\nJune 1, 2024\n12:30pm-1:30pm CDT\nPhase 3 Dose Selection for Selinexor in TP53wt Endometrial Cancer Based on Exposure-Response Analysis\nPoster\n5594\nJune 3, 2024\n9:00am – 12:00pm CDT\nMyelofibrosis\nPhase 3 Trial Design: Randomized Double-Blind Study Evaluating Selinexor, an XPO1 inhibitor, Plus Ruxolitinib in Jaki-Naïve Myelofibrosis\nPoster\nTPS6594\nJune 3, 2024\n9:00am – 12:00pm CDT\nPhase 2 Study Trial Design: Evaluating Selinexor Monothe...